reports
SUCAMPO PHARMACEUTICALS (SCMP) SHAREHOLDER ALERT – Andrews & Springe...
WILMINGTON, Del.--(BUSINESS WIRE)-- Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against Sucampo Pharmaceuticals, Inc. (NASDAQGM: SCMP) (“Sucampo Pharmaceuticals” or the “Company”). If you currently own shares of Sucampo Pharmaceuticals and want to receive additional information and protect your investments free of charge, please visit us at http://www.andrewsspringer.com/cases-investigatio...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Inves...
NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Sucampo Pharmaceuticals, Inc. (“Sucampo” or the “Company”) (NASDAQ GM: SCMP) stock prior to December 27, 2017. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Sucampo to Mallinckrodt plc (NYSE: MNK) for $18.00 in cash per share of Sucampo stock. To learn more about the action and your rights, go to: ...
SUCAMPO PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney W...
DALLAS--(BUSINESS WIRE)-- Former United States Securities and Exchange Commission attorney Willie Briscoe is investigating potential claims against the Board of Directors of Sucampo Pharmaceuticals, Inc. (“Sucampo”) (NASDAQ: SCMP) concerning the sale to Mallinckrodt plc. Under the terms of the agreement, Sucampo shareholders will only receive $18.00 in cash for each share owned, which is virtually no premium over the 52-week high and lower than at least one analyst’s estimated value of $43.00 per share. If you are an affected...
CORRECTINGÂ and REPLACINGÂ Investor Alert: Levi & Korsinsky, LLP Notif...
NEW YORK--(BUSINESS WIRE)-- Third paragraph, first sentence of release should read: You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Sucampo to Mallinckrodt plc (NYSE: MNK) for $18.00 in cash per share of Sucampo stock (instead of ... $28.00 in cash per share of Sucampo stock). The corrected release reads: INVESTOR ALERT: LEVI & KORSINSKY, LLP NOTIFIES INVESTORS OF AN INVESTIGATION CONCERNING WHETHER THE SALE OF SUCAMPO PHARMACEUTICALS, INC. TO ...
SUCAMPO PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A...
WILMINGTON, Del.--(BUSINESS WIRE)-- Rigrodsky & Long, P.A.: Do you own shares of Sucampo Pharmaceuticals, Inc. (NASDAQ GM: SCMP)? Did you purchase any of your shares prior to December 26, 2017? Do you think the proposed buyout is fair? Do you want to discuss your rights? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Sucampo Pharmaceuticals, Inc. (“Sucampo” or the “Company”) (NASDAQ ...
Cancer Prevention Pharmaceuticals Receives $9.5 Million in Additional ...
TUCSON, Ariz.--(BUSINESS WIRE)-- Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced it has received a total of $9.5 million from its North America commercialization partner Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Sucampo paid CPP $4.5 million in option fees and invested $5.0 million in CPP via a convertible note, all in accordance with the terms of the agreements that Sucampo and CPP entered into in January 2016. The payme...
A director bought 4,700 shares at 10.600USD and
A director at Sucampo Pharmaceuticals Inc bought 4,700 shares at 10.600USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.